Table 2.
Differences between different factors of anxiety/depression and non-anxiety/depression patients
| Clinical characteristics | non-anxiety | Anxiety | p | non-depression | depression | p |
|---|---|---|---|---|---|---|
| Age, mean ± sd yearsa | 50.08 ± 11.90 | 51.44 ± 12.90 | 0.508 | 49.69 ± 11.96 | 51.12 ± 12.68 | 0.228 |
| Gender, female, no. (%)b | 100(94.3) | 55 (96.3) | 0.878 | 97(96) | 55 (93.2) | 0.679 |
| Marital status, no. (%)b | 1.000 | 0.401 | ||||
| Married | 100 (94.3) | 51 (94.4) | 97 (96) | 54 (91.5) | ||
| Other marital status | 6 (5.7) | 3 (5.6) | 4 (4) | 5 (8.5) | ||
| Education, years, no. (%)a | 12.43 ± 4.42 | 11.72 ± 4.16 | 0.327 | 13.00 ± 3.96 | 10.81 ± 4.62 | 0.002* |
| Employment status, no. (%)b | 0.064 | 0.049* | ||||
| Employed | 53 (50) | 18 (33.3) | 51 (50.5) | 20 (33.9) | ||
| Unemployed | 53 (50) | 36 (66.7) | 50 (49.5) | 39 (66.1) | ||
| Income/person/year, yuan, no. (%)b | 0.423 | 0.094 | ||||
| < 15,000 yuan | 34 (32.1) | 21 (38.9) | 31 (30.7) | 24 (40.7) | ||
| 15,000-33,000 yuan | 36 (34) | 13 (24.1) | 37 (36.6) | 12 (20.3) | ||
| ≥ 33,000 yuan | 36 (34) | 20 (37) | 33 (32.7) | 23 (39) | ||
| Type of medical insurance, n (%)b | 0.749 | 0.660 | ||||
| With basic medical insurance | 96 (90.6) | 50 (92.6) | 91 (90.1) | 55 (93.2) | ||
| Self-pay | 9 (8.5) | 4 (7.4) | 9 (8.9) | 4 (6.8) | ||
| Other | 1 (0.9) | 0 (0) | 1 (1) | 0 (0) | ||
| Disease duration, mean ± sd yearsa | 4.48 ± 5.61 | 4.53 ± 5.15 | 0.957 | 4.30 ± 4.72 | 4.83 ± 6.53 | 0.557 |
| VAS pain (range 0–10), mean ± sda | 2.12 ± 2.51 | 2.83 ± 2.98 | 0.127 | 2.35 ± 1.95 | 3.07 ± 2.99 | 0.016* |
| ESR, mean ± sd mm/ha | 28.10 ± 21.38 | 35.87 ± 28.47 | 0.085 | 27.10 ± 20.04 | 36.78 ± 29.10 | 0.027* |
| OSDI, mean ± sda | 25.07 ± 22.40 | 37.15 ± 28.28 | 0.008* | 23.82 ± 20.81 | 38.26 ± 29.14 | 0.001* |
| RF positivity, yes, no. (%)b | 29 (46) | 22 (55) | 0.422 | 30 (49.2) | 21 (50) | 1.000 |
| Hospitalization, yes, n (%)b | 68 (64.2) | 40 (74.1) | 0.218 | 68 (67.3) | 40 (67.8) | 1.000 |
| Family history, yes, n (%)b | 15 (14.2) | 8 (14.8) | 1.000 | 17 (16.8) | 6 (10.2) | 0.351 |
| Comorbid conditions, yes, n (%)b | 66 (62.3) | 36 (66.7) | 0.607 | 61 (60.4) | 41 (69.5) | 0.307 |
| ESSDAIa | 9.16 ± 7.73 | 10.48 ± 6.37 | 0.281 | 8.73 ± 7.35 | 11.10 ± 7.03 | 0.047* |
| IgG (g/L)a | 19.05 ± 6.72 | 18.72 ± 6.60 | 0.806 | 18.99 ± 6.54 | 18.84 ± 6.85 | 0.909 |
| C3 (g/L)a | 0.80 ± 0.26 | 0.82 ± 0.28 | 0.781 | 0.80 ± 0.24 | 0.82 ± 0.30 | 0.632 |
| C4 (g/L)a | 0.18 ± 0.07 | 0.17 ± 0.06 | 0.627 | 0.18 ± 0.66 | 0.17 ± 0.06 | 0.552 |
| ANA ≥1: 320b | 61 (91) | 35 (92.1) | 1.000 | 60 (93.8) | 36 (87.8) | 0.481 |
| Anti-SSA ≥ 200 RU/mLb | 54 (80.6) | 31 (81.6) | 1.000 | 50 (78.1) | 35 (85.4) | 0.449 |
| Anti-SSB ≥ 20 RU/mLb | 32 (47.8) | 21 (55.3) | 0.544 | 29 (45.3) | 24 (58.5) | 0.231 |
VAS visual analog scale, ESR erythrocyte sedimentation rate, RF rheumatoid factor, HADS hospital anxiety and depression scale, ESSDAI EULAR Sjögren’s syndrome disease activity index, ANA antinuclear antibodies, IgG immunoglobulin G, C3 complement C3, C4 complement C4, OSDI the ocular surface disease index.* = p<0.05; a = t-tests; b = χ2 analyses